Navigation Links
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Date:2/7/2013

y (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual r
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... of, collaboration with investigators worldwide to develop new treatments for ... diverse forms of cancer ... on relapse rate of patients with early-stage breast cancer, - Four oral ... results of RECORD-1 study in renal cell ...
... Mich. and TOULOUSE, France, May 15 ... company,developing HDL-related compounds for the treatment of ... has completed a Phase I,clinical trial for ... candidates.,CER-002 is a peroxisome proliferator-activated receptor (PPAR),delta-specific ...
Cached Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2
(Date:4/24/2014)... spectrum disorders (ASD), resides in genes that are part ... the Icahn School of Medicine at Mount Sinai, who ... the United States and throughout the world. The ... in Autism Spectrum Disorders," was first published online in ... April 24. , ASD affects about one percent ...
(Date:4/24/2014)... at UT Southwestern Medical Center previously discovered that the ... adult heart lacks this ability. New research by the ... its incredible regenerative capability in adulthood, and the answer ... It is well-known that a major function of the ... But at the same time, oxygen is a highly ...
(Date:4/24/2014)... during and after colorectal surgery cut hospital stays by ... who led a study of the approach at Duke ... easier on patients before surgery, doing away with the ... After surgery, patients are encouraged to eat and move ... , Among findings published in the May 2014 issue ...
(Date:4/24/2014)... and the relevance of palliation in advanced cancer ... controlled trials (RCTs). This is the result of ... and Efficiency in Health Care (IQWiG), which has ... with external experts, IQWiG analysed studies on four ... melanoma, and pancreatic cancer. For this purpose, the ...
(Date:4/24/2014)... first in the world to discover a gene mutation ... , Ameloblastoma is an odontogenic tumour with a high ... found in the posterior of the lower jaw. Ameoloblastomas ... in the jaws as well as loss of several ... for surgery and the recurrence of ameloblastoma, but finding ...
Breaking Medicine News(10 mins):Health News:Genetic alterations in shared biological pathways as major risk factor for ASD 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3
... , ANNAPOLIS, Md., July 27 ... biodefense company developing medical countermeasures against biological and chemical threats, ... issuance of 2-year, 10% unsecured senior convertible notes ("Notes") and ... approximately $19.3 million. , , In connection ...
... , , ... How can hospitals build sustainable physician alignment? While hospitals ... few physician-relationship management programs demonstrate value. A new "thought ... Ensuring the Stability and Vitality of Today,s Hospitals," illustrates ...
... , FRANKLIN, Mass., July 27 ... focused on innovative cardiac and vascular medical device-based technologies, today ... fluid balancing capabilities provided by RenalGuard(R) from the Canadian Intellectual ... company,s first patent for RenalGuard in Canada. , , ...
... reveals more about how information is processed, stored in the ... read her name, your Oprah neuron will probably rev up. ... neurons in the brain,s hippocampus activate when people recognize a ... distorted or presented in less than perfect fashion. , "Different ...
... MINNEAPOLIS, July 27 Premier Visiting Nurse, part ... entered into a business relationship with Cardiocom (R) ... chronic illness. Cardiocom, the Experts in Telehealth(SM), is ... of award-winning telehealth solutions. , , ...
... , , BOSTON, July 27 ... and information management solutions, today announced a new contract with Booth ... use the AMICAS ONE Suite(TM) as its end-to-end radiology software solution, ... care. , , (Logo: ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Proper Physician-Relationship Management Ensures Hospital Stability and Vitality 2Health News:Canada Grants PLC Systems First Patent for RenalGuard(R) 2Health News:Famous Names Get Single Neurons Fired Up 2Health News:Premier Visiting Nurse Selects Cardiocom Telehealth Technology 2Health News:Booth Radiology Extends and Elevates Partnership With AMICAS 2Health News:Booth Radiology Extends and Elevates Partnership With AMICAS 3
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Gently curved shaft with 2 mm platform ideal for performing capsulorhexis through a tunnel incision. Flat handle with dull finish....
Fine angled 12 mm shafts and iris stop. Round handle for fingertip rotational control. Dull finish....
Gently curved jaws with fine angled sharp tips for puncture and grasping the capsule. Round handle is excellent for precise finger tip control. Made in titanium....
Medicine Products: